17-7675176-A-C

Variant summary

Our verdict is Uncertain significance. The variant received 5 ACMG points: 6P and 1B. BP4PM2_SupportingPS4_SupportingPS3

This summary comes from the ClinGen Evidence Repository: The NM_000546.6: c.436T>G variant in TP53 is a missense variant predicted to cause substitution of tryptophan by glycine at amino acid 146 (p.Trp146Gly). This variant has been reported in 2 families, one meeting Classic and one Revised Chompret criteria. Based on this evidence, this variant scores 1.5 total points meeting the TP53 VCEP phenotype scoring criteria of 1-1.5 points. (PS4_Supporting; Internal lab contributors). This variant is absent from gnomAD v4.1.0 (PM2_Supporting). In vitro assays performed in yeast and/or human cell lines showed non-functional transactivation and loss of growth suppression activity indicating that this variant impacts protein function (PS3; PMIDs: 12826609, 30224644). Computational predictor scores (BayesDel = 0.0351; Align GVGD Class 0) are below the recommended thresholds (BayesDel < 0.16 and > -0.008 and an Align GVGD Class ≤ 55), evidence that does not predict a damaging effect on TP53 via protein change. SpliceAI predicts that the variant has no impact on splicing (BP4). In summary, this variant meets the criteria to be classified as Uncertain Significance for Li Fraumeni syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen TP53 VCEP: PS4_Supporting, PM2_Supporting, PS3, BP4. (Bayesian Points: 5; VCEP specifications version 2.3) LINK:https://erepo.genome.network/evrepo/ui/classification/CA000190/MONDO:0018875/009

Frequency

Genomes: not found (cov: 33)

Consequence

TP53
NM_000546.6 missense

Scores

3
6
10

Clinical Significance

Uncertain significance reviewed by expert panel U:2

Conservation

PhyloP100: 1.07

Publications

24 publications found
Variant links:
Genes affected
TP53 (HGNC:11998): (tumor protein p53) This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in this gene are associated with a variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome. Alternative splicing of this gene and the use of alternate promoters result in multiple transcript variants and isoforms. Additional isoforms have also been shown to result from the use of alternate translation initiation codons from identical transcript variants (PMIDs: 12032546, 20937277). [provided by RefSeq, Dec 2016]
TP53 Gene-Disease associations (from GenCC):
  • breast cancer
    Inheritance: AD Classification: DEFINITIVE Submitted by: Ambry Genetics
  • Li-Fraumeni syndrome
    Inheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), G2P, ClinGen, Orphanet
  • Li-Fraumeni syndrome 1
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, Genomics England PanelApp
  • adrenocortical carcinoma, hereditary
    Inheritance: AD Classification: STRONG Submitted by: Ambry Genetics
  • sarcoma
    Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
  • bone marrow failure syndrome 5
    Inheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
  • colorectal cancer
    Inheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
  • choroid plexus carcinoma
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Uncertain_significance. The variant received 5 ACMG points.

PS3
For more information check the summary or visit ClinGen Evidence Repository.
PS4
For more information check the summary or visit ClinGen Evidence Repository.
PM2
For more information check the summary or visit ClinGen Evidence Repository.
BP4
For more information check the summary or visit ClinGen Evidence Repository.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
TP53NM_000546.6 linkc.436T>G p.Trp146Gly missense_variant Exon 5 of 11 ENST00000269305.9 NP_000537.3 P04637-1K7PPA8Q53GA5

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
TP53ENST00000269305.9 linkc.436T>G p.Trp146Gly missense_variant Exon 5 of 11 1 NM_000546.6 ENSP00000269305.4 P04637-1

Frequencies

GnomAD3 genomes
Cov.:
33
GnomAD4 exome
Cov.:
35
GnomAD4 genome
Cov.:
33

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:2
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Li-Fraumeni syndrome Uncertain:1
Mar 04, 2025
ClinGen TP53 Variant Curation Expert Panel, ClinGen
Significance:Uncertain significance
Review Status:reviewed by expert panel
Collection Method:curation

The NM_000546.6: c.436T>G variant in TP53 is a missense variant predicted to cause substitution of tryptophan by glycine at amino acid 146 (p.Trp146Gly). This variant has been reported in 2 families, one meeting Classic and one Revised Chompret criteria. Based on this evidence, this variant scores 1.5 total points meeting the TP53 VCEP phenotype scoring criteria of 1-1.5 points. (PS4_Supporting; Internal lab contributors). This variant is absent from gnomAD v4.1.0 (PM2_Supporting). In vitro assays performed in yeast and/or human cell lines showed non-functional transactivation and loss of growth suppression activity indicating that this variant impacts protein function (PS3; PMIDs: 12826609, 30224644). Computational predictor scores (BayesDel = 0.0351; Align GVGD Class 0) are below the recommended thresholds (BayesDel < 0.16 and > -0.008 and an Align GVGD Class ≤ 55), evidence that does not predict a damaging effect on TP53 via protein change. SpliceAI predicts that the variant has no impact on splicing (BP4). In summary, this variant meets the criteria to be classified as Uncertain Significance for Li Fraumeni syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen TP53 VCEP: PS4_Supporting, PM2_Supporting, PS3, BP4. (Bayesian Points: 5; VCEP specifications version 2.3) -

Hereditary cancer-predisposing syndrome Uncertain:1
Jun 29, 2023
Ambry Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The p.W146G variant (also known as c.436T>G), located in coding exon 4 of the TP53 gene, results from a T to G substitution at nucleotide position 436. The tryptophan at codon 146 is replaced by glycine, an amino acid with highly dissimilar properties. This variant is in the DNA binding domain of the TP53 protein and is reported to have non-functional transactivation in yeast based assays (Kato S et al. Proc. Natl. Acad. Sci. USA. 2003 Jul;100:8424-9). Studies conducted in human cell lines are equivocal about this variant's ability to suppress cell growth (Kotler E et al. Mol.Cell. 2018 Jul;71:178-190.e8; Giacomelli AO et al. Nat. Genet. 2018 Oct;50:1381-1387). This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
0.55
BayesDel_addAF
Pathogenic
0.19
D
BayesDel_noAF
Uncertain
0.040
CADD
Benign
20
DANN
Benign
0.87
DEOGEN2
Uncertain
0.77
D;D;.;.;.;.;D;.;.;.;.;.;.;D;.;.;.;D;D;D
Eigen
Benign
-0.44
Eigen_PC
Benign
-0.60
FATHMM_MKL
Benign
0.27
N
LIST_S2
Benign
0.82
T;T;D;D;D;.;.;.;T;T;.;T;T;T;T;D;D;T;D;D
M_CAP
Pathogenic
0.54
D
MetaRNN
Uncertain
0.50
D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D
MetaSVM
Pathogenic
1.0
D
MutationAssessor
Uncertain
2.5
.;.;.;.;.;.;M;.;M;M;M;.;.;M;.;.;.;.;.;.
PhyloP100
1.1
PrimateAI
Benign
0.45
T
PROVEAN
Benign
-2.1
N;N;.;.;.;.;N;.;.;N;N;.;.;N;.;.;N;D;D;.
REVEL
Uncertain
0.54
Sift
Benign
0.10
T;T;.;.;.;.;T;.;.;T;T;.;.;T;.;.;T;T;D;.
Sift4G
Benign
0.12
T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;.;.;T
Polyphen
0.93
P;.;.;.;.;.;B;.;P;B;P;.;.;B;.;.;.;B;.;.
Vest4
0.47
MutPred
0.61
Gain of disorder (P = 0.0062);Gain of disorder (P = 0.0062);.;.;.;.;Gain of disorder (P = 0.0062);.;Gain of disorder (P = 0.0062);Gain of disorder (P = 0.0062);Gain of disorder (P = 0.0062);.;.;Gain of disorder (P = 0.0062);.;.;.;.;Gain of disorder (P = 0.0062);.;
MVP
0.97
MPC
2.1
ClinPred
0.59
D
GERP RS
0.44
PromoterAI
0.0065
Neutral
Varity_R
0.74
gMVP
0.53

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs786203064; hg19: chr17-7578494; COSMIC: COSV52726362; API